InnoPharmax Competitors

Stocks . Taiwan . 
Stock . InnoPharmax
4172 Stock  TWD 16.75  0.65  4.04%   
InnoPharmax competes with Winston Medical, LIWANLI Innovation, Tsh Biopharmoration, Golden Biotechnology, and Allied Biotech; as well as few others. The company operates under Healthcare sector and is part of Drug Manufacturers - Major industry. Analyzing InnoPharmax competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of InnoPharmax to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out InnoPharmax Correlation with its peers.

InnoPharmax vs Sunny Pharmtech Correlation

Very good diversification

The correlation between InnoPharmax and 6676 is -0.22 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding InnoPharmax and 6676 in the same portfolio, assuming nothing else is changed.

Moving against InnoPharmax Stock

  0.493430 Chitec TechnologyPairCorr
  0.446737 Solid YearPairCorr
  0.414582 Hengs TechnologyPairCorr
  0.376811 Acer E EnablingPairCorr
  0.340053 YuantaP shares TaiwanPairCorr
Hype
Prediction
LowEstimatedHigh
12.8016.2519.70
Details
Intrinsic
Valuation
LowRealHigh
11.0014.4517.90
Details

InnoPharmax Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between InnoPharmax and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of InnoPharmax and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of InnoPharmax does not affect the price movement of the other competitor.

High positive correlations

6130
+ 0.83
8432
4132
+ 0.8
8432
6130
+ 0.8
4132
8432
+ 0.61
3054
6709
+ 0.61
1796
6676
+ 0.51
1780
  

High negative correlations

6676
- 0.76
4132
6676
- 0.73
8432
6676
- 0.69
6130
1780
- 0.67
4132
1780
- 0.67
8432
6709
- 0.65
3054

Risk-Adjusted Indicators

There is a big difference between InnoPharmax Stock performing well and InnoPharmax Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze InnoPharmax's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
6817  1.36 (0.41) 0.00 (1.21) 0.00 
 0.00 
 3.49 
(3.49)
 8.49 
3054  1.50  0.48  0.22 (34.82) 1.23 
(1.86)
 3.97 
(2.54)
 14.35 
8432  0.87  0.04 (0.04)(0.18) 1.07 
(1.06)
 1.85 
(1.45)
 8.37 
4132  4.43  0.82  0.14 (3.84) 4.55 
(5.22)
 12.15 
(6.05)
 45.53 
1780  1.48  0.22  0.08 (0.78) 1.39 
(1.91)
 3.66 
(2.95)
 14.51 
1762  0.67 (0.04) 0.00 (0.12) 0.00 
 0.00 
 1.63 
(1.18)
 4.75 
1796  1.19 (0.16) 0.00  1.33  0.00 
 0.00 
 2.58 
(2.83)
 7.77 
6709  1.67 (0.36) 0.00 (0.60) 0.00 
 0.00 
 3.20 
(3.71)
 16.90 
6130  1.87  0.09  0.00 (0.13) 2.13 
(2.27)
 3.95 
(3.84)
 14.17 
6676  2.23  0.44  0.14 (3.54) 1.99 
(2.99)
 5.26 
(4.47)
 22.10 

InnoPharmax Competitive Analysis

The better you understand InnoPharmax competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, InnoPharmax's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across InnoPharmax's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
4172 6817 3054 8432 4132 1780 1762 1796 6709 6130
 4.04 
 16.75 
InnoPharmax
 2.97 
 86.60 
Winston
 0.94 
 31.60 
LIWANLI
 0.71 
 56.90 
Tsh
 11.89 
 18.35 
Golden
 0.40 
 24.90 
Allied
 2.61 
 27.50 
Chunghwa
 0.78 
 45.35 
GeneFerm
 7.28 
 30.95 
Advagene
 3.93 
 41.60 
Singbao
Market Volatility
(90 Days Market Risk)
Not too volatile
Very steady
Very steady
Very steady
Somewhat reliable
Not too volatile
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Weakest
Weakest
Solid
Mild
Fair
Mild
Mild
Weakest
Weakest
Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Low
Small
Low
Low
Low
Low
Low
Fair
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Fairly Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Hold
Strong Sell
Cautious Hold
Strong Sell
Current Ratio
3.74
1.65
10.27
5.36
2.78
2.19
1.36
1.98
N/A
N/A
Net Asset
N/A
N/A
947.9 M
1.17 B
N/A
N/A
4.38 B
1.32 B
N/A
550.64 M
Profit Margin
-152.85
24.57
-2.88
0.15
N/A
19.15
0.23
0.15
N/A
-0.11
EBITDA
(70.64 M)
177.79 M
65.26 M
71.41 M
(279.28 M)
190.03 M
632.93 M
123.07 M
N/A
59.36 M
Operating Margin
-142.06
24.46
-1.15
0.16
-414.69
19.21
0.22
0.17
N/A
-0.27
Current Valuation
641.19 M
1.22 B
1.2 B
1.17 B
5.17 B
1.49 B
5.19 B
2.48 B
N/A
1.09 B
Price To Book
1.34
4.51
2.04
1.77
6.75
1.48
1.56
2.94
N/A
1.81
Retained Earnings
N/A
N/A
18 M
N/A
N/A
N/A
630 M
N/A
N/A
N/A
Current Asset
N/A
N/A
794 M
N/A
N/A
N/A
729 M
N/A
N/A
N/A
Five Year Return
N/A
N/A
N/A
3.54
N/A
N/A
2.83
N/A
N/A
N/A
Beta
0.11
N/A
0.0508
-0.0266
0.72
0.24
0.86
0.89
N/A
0.0463
Number Of Employees
38
N/A
19
80
135
11
21
12
10
17
Shares Outstanding
70.55 M
18.17 M
80.65 M
38.4 M
115.76 M
94.6 M
77.56 M
41.46 M
N/A
44.3 M
Cash Flow From Operations
(70.17 M)
169.12 M
(61.13 M)
68.71 M
(306.43 M)
172.94 M
219.18 M
112.23 M
N/A
1.9 M
Annual Yield
N/A
N/A
N/A
0.0319
N/A
N/A
0.0198
0.0139
N/A
N/A
Total Debt
N/A
136.16 M
2.13 M
7.01 M
227.3 M
484.99 M
600 M
31.25 M
N/A
11.71 M
Return On Equity
-14.75
53.39
-0.12
0.0635
-36.95
12.11
0.17
0.12
N/A
-0.0194
Z Score
N/A
5.4
N/A
N/A
13.2
1.8
4.8
61.8
N/A
85.2
Return On Asset
-8.13
13.76
-0.0274
0.0387
-17.85
4.62
0.066
0.0534
N/A
-0.0208
Book Value Per Share
7.7
16.2
9.56
27.67
6.59
11.93
39.98
19.63
N/A
16.84
Current Liabilities
N/A
N/A
409 M
N/A
N/A
N/A
617 M
N/A
N/A
N/A
Total Asset
N/A
N/A
947.9 M
1.17 B
N/A
N/A
4.38 B
1.32 B
N/A
550.64 M
Debt To Equity
N/A
0.39
0.002
0.6
30.1
43.0
41.0
0.72
N/A
N/A
Last Dividend Paid
N/A
3.0
N/A
1.5
N/A
1.0
1.3
N/A
N/A
N/A
Target Price
N/A
N/A
N/A
N/A
N/A
N/A
125.0
N/A
N/A
N/A
Shares Owned By Institutions
N/A
N/A
N/A
N/A
N/A
N/A
4.61
N/A
N/A
N/A
Market Capitalization
715.45 M
1.33 B
1.52 B
1.78 B
5.15 B
1.66 B
5.17 B
3.22 B
879.46 M
1.66 B
Price To Earning
N/A
13.01
156.1
56.63
N/A
12.39
9.2
53.28
N/A
N/A
Price To Sales
12.66
2.26
45.98
4.22
65.71
2.38
2.37
4.16
N/A
15.08
Net Income
(86.35 M)
144.27 M
45.56 M
47.11 M
(336.49 M)
134.05 M
400.78 M
57.41 M
N/A
32.47 M
Earnings Per Share
-1.23
5.62
0.18
1.78
-2.97
1.42
6.21
2.18
N/A
0.11
Shares Owned By Insiders
N/A
N/A
81.86
64.94
N/A
N/A
39.75
57.17
N/A
53.43
Revenue
56.49 M
587.22 M
47.81 M
413.48 M
78.35 M
699.9 M
1.93 B
522.33 M
N/A
103.81 M
Working Capital
N/A
N/A
385 M
N/A
N/A
N/A
112 M
N/A
N/A
N/A
Cash And Equivalents
99.55 M
238.7 M
661.45 M
708.28 M
152.56 M
676.58 M
97.43 M
619.1 M
N/A
N/A
Cash Per Share
1.41
13.14
7.93
18.36
1.33
7.17
1.26
15.32
N/A
N/A
Gross Profit
27.82 M
203.82 M
7.54 M
247.36 M
51.31 M
301.27 M
949.39 M
192.65 M
N/A
53.69 M
Day Typical Price
16.45
84.87
31.67
56.67
17.92
24.63
27.47
45.9
30.37
42.37
Accumulation Distribution
27232.55
2812.98
2261.76
681.93
272989.0
17172.38
15527.12
456.38
10405.56
19386.8
Market Facilitation Index
0.0
1.0E-4
0.0
0.0
0.0
0.0
0.0
1.0E-4
0.0
0.0
Daily Balance Of Power
0.7222
0.463
(0.23)
0.5714
0.6964
(0.08)
0.7
0.2121
1.02439
(0.74)
Period Momentum Indicator
0.65
2.5
(0.30)
0.4
1.95
(0.10)
0.7
0.35
2.1
(1.70)
Rate Of Daily Change
1.04
1.03
0.99
1.01
1.12
1.0
1.03
1.01
1.07
0.96
Day Median Price
16.3
84.0
31.7
56.55
17.7
24.5
27.45
46.18
30.08
42.75
Price Action Indicator
0.77
3.85
(0.25)
0.55
1.63
0.35
0.4
(0.65)
1.92
(2.00)
Relative Strength Index
N/A
N/A
63.09
55.0
48.85
N/A
71.12
43.72
58.82
46.47
Coefficient Of Variation
13570.23
(507.25)
448.31
3315.18
813.7
1165.16
(6,955)
(961.98)
(829.29)
3601.58
Mean Deviation
2.38
1.36
1.5
0.8714
4.43
1.48
0.6749
1.19
1.67
1.87
Jensen Alpha
0.0256
(0.41)
0.478
0.0381
0.8227
0.2192
(0.04)
(0.16)
(0.36)
0.0918
Total Risk Alpha
(0.32)
(0.57)
0.2659
(0.09)
0.1644
(0.04)
(0.12)
(0.32)
(0.57)
(0.18)
Sortino Ratio
(0.02)
N/A
0.2212
(0.04)
0.142
0.0805
N/A
N/A
N/A
(0)
Downside Variance
6.79
N/A
3.37
1.4
26.92
2.61
N/A
N/A
N/A
5.16
Standard Deviation
3.45
1.91
2.18
1.24
6.65
2.46
1.02
1.57
2.59
2.53
Kurtosis
3.11
1.13
5.04
3.66
7.05
13.69
3.94
0.2287
8.49
1.33
Potential Upside
9.31
3.49
3.97
1.85
12.15
3.66
1.63
2.58
3.2
3.95
Treynor Ratio
(0.11)
(1.21)
(34.82)
(0.18)
(3.84)
(0.78)
(0.12)
1.33
(0.60)
(0.13)
Maximum Drawdown
19.46
8.49
14.35
8.37
45.53
14.51
4.75
7.77
16.9
14.17
Variance
11.9
3.64
4.77
1.53
44.28
6.04
1.03
2.45
6.72
6.38
Market Risk Adjusted Performance
(0.1)
(1.20)
(34.81)
(0.17)
(3.83)
(0.77)
(0.11)
1.34
(0.59)
(0.12)
Risk Adjusted Performance
0.0133
(0.14)
0.1703
0.0262
0.0991
0.07
(0.01)
(0.07)
(0.08)
0.0275
Skewness
1.07
0.2925
1.36
0.4061
1.74
2.94
1.31
0.2016
1.88
0.5686
Semi Deviation
2.49
N/A
1.23
1.07
4.55
1.39
N/A
N/A
N/A
2.13
Information Ratio
(0.02)
(0.24)
0.186
(0.04)
0.1107
0.0529
(0.09)
(0.16)
(0.15)
(0)
Value At Risk
(4.26)
(3.49)
(2.54)
(1.45)
(6.05)
(2.95)
(1.18)
(2.83)
(3.71)
(3.84)
Expected Short fall
(3.59)
N/A
(1.86)
(1.06)
(5.22)
(1.91)
N/A
N/A
N/A
(2.27)
Downside Deviation
2.61
N/A
1.84
1.19
5.19
1.62
N/A
N/A
N/A
2.27
Semi Variance
6.22
N/A
1.52
1.14
20.72
1.92
N/A
N/A
N/A
4.53

InnoPharmax Competition Performance Charts

Five steps to successful analysis of InnoPharmax Competition

InnoPharmax's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by InnoPharmax in relation to its competition. InnoPharmax's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of InnoPharmax in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact InnoPharmax's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to InnoPharmax, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your InnoPharmax position

In addition to having InnoPharmax in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Agency Mbs ETFs Thematic Idea Now

Agency Mbs ETFs
Agency Mbs ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Agency Mbs ETFs theme has 12 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Agency Mbs ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for InnoPharmax Stock Analysis

When running InnoPharmax's price analysis, check to measure InnoPharmax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InnoPharmax is operating at the current time. Most of InnoPharmax's value examination focuses on studying past and present price action to predict the probability of InnoPharmax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InnoPharmax's price. Additionally, you may evaluate how the addition of InnoPharmax to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY